Skip to main content

Table 4 Associations of CYP19A1 and ESR1 genotypes with analysis endpoints

From: Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

   

Univariate model

Multivariableb model

Multivariablec model

Gene: SNP

Comparisons

Numbera (events)

Odds ratio (95 % CI)

P value

Odds ratio (95 % CI)

P value

Odds ratio (95 % CI)

P value

Hot flashes/sweating

  CYP19A1: rs4646

Dose effectd

1965 (848)

1.05 (0.91,1.21)

0.50

1.04 (0.90,1.20)

0.63

1.08 (0.93,1.25)

0.30

  CYP19A1: rs10046

T/T vs. C/T,C/C (ref)

446 (172) vs. 1519 (676)

0.78 (0.63,0.97)

0.03

0.82 (0.66,1.02)

0.08

0.83 (0.66,1.04)

0.10

  ESR1:rs2077647

Dose effect

1965 (848)

0.95 (0.84,1.08)

0.47

0.96 (0.84,1.09)

0.51

0.97 (0.85,1.11)

0.69

  ESR1:rs2234693 (PvuII)

Dose effect

1965 (848)

0.92 (0.80,1.04)

0.18

0.92 (0.80,1.04)

0.19

0.94 (0.82,1.07)

0.36

  ESR1:rs9340799 (XbaI)

Dose effect

1965 (848)

0.94 (0.82,1.08)

0.38

0.94 (0.82,1.07)

0.34

0.98 (0.85,1.12)

0.73

Musculoskeletal symptoms

  CYP19A1: rs4646

Dose effectd

1966 (516)

1.01 (0.86,1.18)

0.90

1.05 (0.89,1.24)

0.55

1.11 (0.93,1.31)

0.25

  CYP19A1: rs10046

T/T vs. C/T,C/C (ref)

446 (110) vs. 1520 (406)

0.90 (0.70,1.15)

0.39

0.86 (0.66,1.10)

0.23

0.84 (0.65,1.09)

0.18

  ESR1:rs2077647

Dose effect

1966 (516)

1.08 (0.94,1.25)

0.28

1.12 (0.96,1.30)

0.15

1.11 (0.95,1.29)

0.20

  ESR1:rs2234693 (PvuII)

Dose effect

1966 (516)

1.03 (0.90,1.19)

0.65

1.07 (0.92,1.25)

0.37

1.06 (0.91,1.24)

0.47

  ESR1:rs9340799 (XbaI)

Dose effect

1966 (516)

1.06 (0.91,1.23)

0.44

1.10 (0.94,1.29)

0.22

1.11 (0.94,1.30)

0.22

  1. Analysis endpoints were early-onset (within 6 months) grade ≥2 hot flashes/sweating or (within 12 months) grade ≥2 musculoskeletal symptoms. aPatients without any adverse event data, excluded from analyses (2 without hot flashes/sweating and one without musculoskeletal symptoms). bMultivariable logistic regression model adjusted for characteristics: age, menstruation status, BMI, adjuvant chemotherapy use, treatment assignment, and presence of hot flashes/sweating at baseline or of musculoskeletal symptoms at baseline (according to endpoint). cMultivariable model also adjusted for relevant concomitant medications prior to or continuing at baseline, and use during relevant time period for the endpoint. dDose effect: comparisons of variant (Var) allele groups: 0 (Var) vs. 1 (Var) vs. 2 (Var). SNP single nucleotide polymorphism